Stock Analysis, Dividends, Split History

CASC / Cascadian Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price10.02
Volume438,200.00
Market Cap ($M)554.28
Enterprise Value ($M)537.50
Book Value ($M)109.04
Book Value / Share1.97
Price / Book5.08
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 50,598,611
Common Shares Outstanding 55,317,212
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.52
Return on Assets (ROA)-0.68
Return on Equity (ROE)-0.77
Balance Sheet (mrq) ($M)
Assets120.83
Liabilities11.79
Quick Ration/a
Current Ratio8.07
Income Statement (mra) ($M)
Operating Income-58.09
Net Income-56.93
Earnings Per Share Basic And Diluted-1.21
Cash Flow Statement (mra) ($M)
Cash From Operations-49.98
Cash from Investing-35.34
Cash from Financing-35.34
Identifiers and Descriptors
CUSIP682324108
Central Index Key (CIK)1412067
Related CUSIPS
147195101 14740B906 14740B901 14740B956 14740B951 14740B606

Split History

Stock splits are used by Cascadian Therapeutics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

Related News Stories

Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates

2018-07-27 zacks
Seattle Genetics Inc., (SGEN - Free Report) reported a loss of 18 cents per share for the second quarter of 2018, narrower than the Zacks Consensus Estimate of 34 cents and the year-ago quarter’s loss of 39 cents. (1-0)

More than $100 Billion Spent on M&A in the First 6 Months of 2018

2018-07-06 biospace
For many biotech companies, mergers and acquisitions have become a cornerstone in building a robust pipeline that can ensure positive growth for years to come. Although 2017 was slow for M&A activity, analysts have predicted 2018 could be a return to a spending frenzy. (62-0)

Institutional Top Ideas: Great Point Partners

2018-06-19 seekingalpha
Great Point Partners has high returns of late and a significantly concentrated portfolio while avoiding extreme overweighting we´ve seen with certain other funds. (161-2)

Why Is Seattle Genetics (SGEN) Up 13.3% Since Its Last Earnings Report?

2018-05-28 zacks
It has been about a month since the last earnings report for Seattle Genetics, Inc. (SGEN - Free Report) . Shares have added about 13.3% in that time frame. (27-1)

Tracking Seth Klarman's Baupost Group Holdings - Q1 2018 Update

2018-05-15 seekingalpha
The portfolio continues to be heavily concentrated, with the top three positions accounting for one-third of the 13F portfolio. (408-18)

JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond

2018-05-01 seekingalpha
I remind readers that I am not a market timer, as I have no edge in making predictions. (579-2)

Seattle Genetics (SGEN) Q1 Earnings Lag Estimates, Sales Top

2018-04-27 zacks
Seattle Genetics, Inc. (SGEN - Free Report) reported a loss of 61 cents per share for the first quarter of 2018, wider than the Zacks Consensus Estimate of 40 cents and the year-ago quarter loss of 42 cents. (43-0)

Seattle Genetics (SGEN) Q1 2018 Results - Earnings Call Transcript

2018-04-27 seekingalpha
Good day, and welcome to the Seattle Genetics Business Update Conference Call. Today's conference is being recorded. At this time, I'd like to turn the conference over to Peggy Pinkston, Vice President of Investor Relations. Please go ahead, ma'am. (24-0)

Institutional Top Ideas Series: Baker Brothers

2018-04-25 seekingalpha
Today's fund in the spotlight, Baker Brothers, has been struggling of late but as long term investors they´ve chalked up an impressive track record. (107-8)

Reader Inquiry: What's The Outlook For Atara Biotherapeutics After The Recent Secondary?

2018-04-20 seekingalpha
The stock has more than doubled since I suggested investors buy shares after January´s secondary offering. (27-0)

CUSIP: 682324108